Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15038MR)

This product GTTS-WQ15038MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15038MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4313MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ13110MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ12107MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ1127MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ9023MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ4143MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ13713MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ4346MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW